(Q56897804)

English

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (

article published in 2004

In more languages

Statements

scholarly article

0 references

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels ( (English)

0 references

object named as

M Floridia

1

0 references

author name string

M Floridia

1

0 references

R Bucciardini

2

0 references

V Fragola

3

0 references

C M Galluzzo

4

0 references

G Giannini

5

0 references

M F Pirillo

6

0 references

R Amici

7

0 references

M Andreotti

8

0 references

D Ricciardulli

9

0 references

C Tomino

10

0 references

S Vella

11

0 references

CM Galluzzo

4

0 references

MF Pirillo

6

0 references

language of work or name

0 references

publication date

January 2004

0 references

0 references

5

0 references

1

0 references

1-10

0 references

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Sex differences in nevirapine rash

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Predictors of protease inhibitor-associated adverse events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00177.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2004.00177.X

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56897804&oldid=1875314611"